Clinical Features, Endoscopic Findings, and Predictive Factors for Mortality in Tissue-Invasive Gastrointestinal Cytomegalovirus Disease between Immunocompetent and Immunocompromised Patients
Table 3
Treatments and outcomes of TI-GI CMV disease between immunocompromised and immunocompetent patients.
Treatment and outcomes
Overall ()
Immunocompromised ()
Immunocompetent ()
value
Antiviral treatment
173 (81.2)
93 (75.0)
80 (89.9)
0.010
Ganciclovir
163 (76.5)
90 (72.6)
73 (82.0)
0.150
Valganciclovir
10 (16.9)
3 (22.6)
7 (0.09)
0.225
Duration of treatment in days, mean (SD)
19.6 (9.7)
20.1 (8.9)
19.0 (10.5)
0.456
Time to follow-up endoscopy in days, mean (SD)
24.7 (7.3)
23.4 (7.4)
26.6 (8.7)
0.673
Symptomatic improvement after antiviral treatment†
127 (73.4)
70 (75.3)
57 (71.3)
0.115
Endoscopic follow-up
97 (45.5)
54 (43.5)
43 (48.3)
0.671
Complete improvement‡
25 (25.8)
11 (20.4)
14 (32.6)
0.048
Partially improvement‡
59 (60.8)
36 (66.7)
23 (53.5)
0.180
Not improvement.
13 (13.4)
7 (13.0)
6 (14.0)
0.725
Histological improvement‡
78 (80.4)
42 (77.8)
36 (83.7)
0.365
Perforation
2 (0.9)
1 (0.8)
1 (1.1)
1.000
Recurrence infection
8 (3.8)
7 (5.6)
1 (1.1)
0.143
Inhospital dead
59 (27.7)
34 (27.4)
25 (28.1)
0.812
Spontaneous symptoms and/or endoscopic improvement without antiviral treatment
8 (3.8) (20% of non-treatment)
3 (1.4) (9.7% of non-treatment)
5 (5.6) (55% of non-treatment)
0.035
Data are presented as number (percentage) unless indicated otherwise. †Symptomatic improvement was calculated based on number of patients who received antiviral treatment ‡Endoscopic and histological improvement were calculated based on number of patients who underwent follow-up endoscopy.
